174 related articles for article (PubMed ID: 36525420)
1. Anti-GRP-R monoclonal antibody antitumor therapy against neuroblastoma.
Qiao J; Liu J; Jacobson JC; Clark RA; Lee S; Liu L; An Z; Zhang N; Chung DH
PLoS One; 2022; 17(12):e0277956. PubMed ID: 36525420
[TBL] [Abstract][Full Text] [Related]
2. Gastrin-releasing peptide receptor silencing suppresses the tumorigenesis and metastatic potential of neuroblastoma.
Qiao J; Kang J; Ishola TA; Rychahou PG; Evers BM; Chung DH
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):12891-6. PubMed ID: 18753628
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylinositol 3-kinase regulation of gastrin-releasing peptide-induced cell cycle progression in neuroblastoma cells.
Ishola TA; Kang J; Qiao J; Evers BM; Chung DH
Biochim Biophys Acta; 2007 Jun; 1770(6):927-32. PubMed ID: 17379415
[TBL] [Abstract][Full Text] [Related]
4. Gastrin-releasing peptide is a growth factor for human neuroblastomas.
Kim S; Hu W; Kelly DR; Hellmich MR; Evers BM; Chung DH
Ann Surg; 2002 May; 235(5):621-9; discussion 629-30. PubMed ID: 11981207
[TBL] [Abstract][Full Text] [Related]
5. FAK is a critical regulator of neuroblastoma liver metastasis.
Lee S; Qiao J; Paul P; O'Connor KL; Evers MB; Chung DH
Oncotarget; 2012 Dec; 3(12):1576-87. PubMed ID: 23211542
[TBL] [Abstract][Full Text] [Related]
6. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes.
Zhou J; Chen J; Zhong R; Mokotoff M; Shultz LD; Ball ED
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2224-31. PubMed ID: 16609038
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.
Wu HW; Sheard MA; Malvar J; Fernandez GE; DeClerck YA; Blavier L; Shimada H; Theuer CP; Sposto R; Seeger RC
Clin Cancer Res; 2019 Aug; 25(15):4761-4774. PubMed ID: 31068371
[TBL] [Abstract][Full Text] [Related]
8. TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.
Tran HC; Wan Z; Sheard MA; Sun J; Jackson JR; Malvar J; Xu Y; Wang L; Sposto R; Kim ES; Asgharzadeh S; Seeger RC
Clin Cancer Res; 2017 Feb; 23(3):804-813. PubMed ID: 27756784
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
Sondel PM; Hank JA
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
[TBL] [Abstract][Full Text] [Related]
11. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.
Kroesen M; Nierkens S; Ansems M; Wassink M; Orentas RJ; Boon L; den Brok MH; Hoogerbrugge PM; Adema GJ
Int J Cancer; 2014 Mar; 134(6):1335-45. PubMed ID: 24038106
[TBL] [Abstract][Full Text] [Related]
12. Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer.
Zhou J; Chen J; Mokotoff M; Zhong R; Shultz LD; Ball ED
Clin Cancer Res; 2003 Oct; 9(13):4953-60. PubMed ID: 14581370
[TBL] [Abstract][Full Text] [Related]
13. Akt2 regulates metastatic potential in neuroblastoma.
Qiao J; Lee S; Paul P; Qiao L; Taylor CJ; Schlegel C; Colon NC; Chung DH
PLoS One; 2013; 8(2):e56382. PubMed ID: 23468863
[TBL] [Abstract][Full Text] [Related]
14. Silencing gastrin-releasing peptide receptor suppresses key regulators of aerobic glycolysis in neuroblastoma cells.
Rellinger EJ; Romain C; Choi S; Qiao J; Chung DH
Pediatr Blood Cancer; 2015 Apr; 62(4):581-6. PubMed ID: 25630799
[TBL] [Abstract][Full Text] [Related]
15. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages.
Lum HD; Buhtoiarov IN; Schmidt BE; Berke G; Paulnock DM; Sondel PM; Rakhmilevich AL
J Leukoc Biol; 2006 Jun; 79(6):1181-92. PubMed ID: 16565324
[TBL] [Abstract][Full Text] [Related]
16. Differential regulation of cyclin-dependent kinase inhibitors in neuroblastoma cells.
Qiao L; Paul P; Lee S; Qiao J; Wang Y; Chung DH
Biochem Biophys Res Commun; 2013 May; 435(2):295-9. PubMed ID: 23618860
[TBL] [Abstract][Full Text] [Related]
17. Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.
Liu X; Carlisle DL; Swick MC; Gaither-Davis A; Grandis JR; Siegfried JM
Exp Cell Res; 2007 Apr; 313(7):1361-72. PubMed ID: 17349623
[TBL] [Abstract][Full Text] [Related]
18. Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy.
Singha NC; Nekoroski T; Zhao C; Symons R; Jiang P; Frost GI; Huang Z; Shepard HM
Mol Cancer Ther; 2015 Feb; 14(2):523-32. PubMed ID: 25512619
[TBL] [Abstract][Full Text] [Related]
19. GD2 ganglioside specific antibody treatment downregulates PI3K/Akt/mTOR signaling network in human neuroblastoma cell lines.
Durbas M; Horwacik I; Boratyn E; Kamycka E; Rokita H
Int J Oncol; 2015 Sep; 47(3):1143-59. PubMed ID: 26134970
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model.
Williams EL; Dunn SN; James S; Johnson PW; Cragg MS; Glennie MJ; Gray JC
Clin Cancer Res; 2013 Jul; 19(13):3545-55. PubMed ID: 23649004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
